

Signaling Circuits in Cancer Programme

Virtual Event, Worldwide

13 - 14 February 2024



Scientific Programme

Tuesday 13th February 2024

Listed times are in Central European Time (CET)

13:00 **WELCOME TO DAY ONE**

Chair: Jukka Westermarck

13:05 **Stephin Vervoort**

Walter and Eliza Hall Institute of Medical Research, Australia

"The Rise of the Anti-Terminators: How CDK12/13 combat transcriptional terminators to keep RNA Polymerase II on course"

Q&A 13:25 - 13:35

13:35 **Mutsuhiro Takekawa**

University of Tokyo, Japan

"Transcriptional regulation of immediate-early genes by a novel ERK substrate protein and its failure in cancer"

Q&A 13:55 - 14:05

14:05 **Tim Lebedev**

Engelhardt Institute of Molecular Biology, Russia

Proffered Paper 1: "Pan-cancer profiling of ERK1/2 activity with single cell imaging predicts anticancer drug synergy with ERK inhibitors."

Q&A 14:15 - 14:20

14:20 Refreshment break

Chair: Chiara Ambrogio

14:40 **Jukka Westermarck**

Turku Bioscience Centre, University of Turku, Finland

"DUSP6 inhibition overcomes Neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer"

Q&A 15:00 - 15:10

15:10 **Mariangela Russo**

University of Turin, Italy

"Leveraging DNA Damage Response to prevent secondary resistance to MAPK pathway inhibition"

Q&A 15:30 - 15:40

15:40 **Dan Lu**

Harvard Medical School, USA

Proffered Paper 2: "Integration of p53 dynamics and modifications regulate temporal therapeutic response"

Q&A 15:50 - 15:55

15:55 Refreshment break

- 16:15 **Gad Getz**
Broad Institute, USA
"Finding mechanisms of resistance in cancer"
Q&A 16:35 - 16:45
- 16:45 **POSTER SPOTLIGHTS**
- 16:55 **DAY 1 SUMMARY**
- 17:05 Transition break
- 17:20 **VIRTUAL POSTER DISCUSSION SESSION ONE**

Wednesday 14th February 2024

Listed times are in Central European Time (CET)

- 12:30 **VIRTUAL POSTER DISCUSSION SESSION TWO**
- 13:30 Transition break
- 14:00 **WELCOME TO DAY TWO**
Chair: Yaara Oren
- 14:05 **Bernhard Küster**
Technical University of Munchen, Germany
"Decrypting drug actions and protein modifications by dose- and time-resolved proteomics"
Q&A 14:25 - 14:35
- 14:35 **Jean-Emmanuel Sarry**
Toulouse Cancer Research Center, France
"Mitochondrial signaling circuits in response to therapy of acute myeloid leukemia."
Q&A 14:55 - 15:05
- 15:05 **Alessandra Allotta**
Royal College of Surgeons in Ireland, Ireland
Proffered Paper 3: "Insights into the biological effect of targeting CDK12 in advanced ER+ breast cancer"
Q&A 15:15 - 15:20
- 15:20 Refreshment break
Chair: Jukka Westermarck
- 15:40 **Nikhil Gupta**
Turku Bioscience Centre, Finland
Proffered Paper 4: "Species-specific differences in Malignant Transformation: Role of PP2A and its implications for cancer therapy"
Q&A 15:50 - 15:55
- 15:55 **Yaara Oren**
Tel Aviv University, Israel
"Identifying the mechanisms underlying persistence potential and drug-induced cellular memory"
Q&A 16:15 - 16:25

- 16:25 **Sydney Shaffer**
University of Pennsylvania, USA
"Tracking the origins of metaplasia and cancer"
Q&A 16:45 - 16:55
- 16:55 Refreshment break
- 17:15 **Michelle Arkin**
University of California San Francisco, USA
"Modulating Cancer Networks with Molecular Glues"
Q&A 17:35 - 17:45
- 17:45 **CONFERENCE SUMMARY**
Our Scientific Programme Committee members, Jukka Westermarck, Chiara Ambrogio and Yaara Oren will join together to deliver their thoughts and a summary of the meeting.